CYTOKINETICS, INCORPORATED Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
CYTOKINETICS, INCORPORATED (CYTK) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 1.28 million shares for the 9-month period ending 2017-09-30, per its 10-Q filed 2017-11-03.
Discontinued › Shareholders' Equity
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2017-11-03
- CYTOKINETICS, INCORPORATED share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2017-09-30 was 109.30K shares, a 447.18% increase year-over-year.
- CYTOKINETICS, INCORPORATED share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2017-06-30 was 294.85K shares, a 33.00% increase year-over-year.
- CYTOKINETICS, INCORPORATED share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2017-03-31 was 874.77K shares, a 25.50% decline year-over-year.
- CYTOKINETICS, INCORPORATED share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2016-12-31 was 30.80K shares, a 42.59% increase year-over-year.
- CYTOKINETICS, INCORPORATED share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2016 was 1.45M shares, a 23.04% increase from fiscal 2015.
- CYTOKINETICS, INCORPORATED share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2015 was 1.18M shares, a 24.44% increase from fiscal 2014.
- CYTOKINETICS, INCORPORATED share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2014 was 944.83K shares, a 18.45% increase from fiscal 2013.
- CYTOKINETICS, INCORPORATED share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2013 was 797.63K shares, a 97.87% increase from fiscal 2012.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month as first filed |
|---|---|---|---|---|---|
| 2017-09-30 | 109.30K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-03 | 404.15K shares derived: sum of 2 quarters · filed 2017-11-03 | 1.28M shares 10-Q · filed 2017-11-03 | 1.31M shares derived: sum of 4 quarters · filed 2017-11-03 | |
| 2017-06-30 | 294.85K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-04 | 1.17M shares 10-Q · filed 2017-08-04 | 1.20M shares derived: sum of 3 quarters · filed 2017-08-04 | 1.22M shares derived: sum of 4 quarters · filed 2017-08-04 | |
| 2017-03-31 | 874.77K shares 10-Q · filed 2017-05-04 | 905.57K shares derived: sum of 2 quarters · filed 2017-05-04 | 925.55K shares derived: sum of 3 quarters · filed 2017-05-04 | 1.15M shares derived: sum of 4 quarters · filed 2017-05-04 | |
| 2016-12-31 | 30.80K shares derived: 10-K 12 month − 10-Q/A 9 month · filed 2017-03-06 | 50.77K shares derived: sum of 2 quarters · filed 2017-03-06 | 272.48K shares derived: sum of 3 quarters · filed 2017-03-06 | 1.45M shares 10-K · filed 2017-03-06 | |
| 2016-09-30 | 19.98K shares derived: 10-Q/A 9 month − 10-Q 6 month · filed 2016-12-15 | 241.68K shares derived: sum of 2 quarters · filed 2016-12-15 | 1.42M shares 10-Q/A · filed 2016-12-15 | 1.44M shares derived: sum of 4 quarters · filed 2017-03-06 | |
| 2016-06-30 | 221.70K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | 1.40M shares 10-Q · filed 2016-08-04 | 1.42M shares derived: sum of 3 quarters · filed 2017-03-06 | 1.45M shares derived: sum of 4 quarters · filed 2017-03-06 | |
| 2016-03-31 | 1.17M shares 10-Q · filed 2016-05-05 | 1.20M shares derived: sum of 2 quarters · filed 2017-03-06 | 1.23M shares derived: sum of 3 quarters · filed 2017-03-06 | 1.47M shares derived: sum of 4 quarters · filed 2017-03-06 | |
| 2015-12-31 | 21.60K shares derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-06 | 55.55K shares derived: sum of 2 quarters · filed 2017-03-06 | 296.20K shares derived: sum of 3 quarters · filed 2017-03-06 | 1.18M shares 10-K · filed 2017-03-06 | |
| 2015-09-30 | 33.95K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-05 | 274.60K shares derived: sum of 2 quarters · filed 2015-11-05 | 1.15M shares 10-Q · filed 2015-11-05 | 1.18M shares derived: sum of 4 quarters · filed 2017-03-06 | |
| 2015-06-30 | 240.65K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-05 | 1.12M shares 10-Q · filed 2015-08-05 | 1.14M shares derived: sum of 3 quarters · filed 2017-03-06 | 1.15M shares derived: sum of 4 quarters · filed 2017-03-06 | |
| 2015-03-31 | 879.53K shares 10-Q · filed 2015-05-04 | 903.48K shares derived: sum of 2 quarters · filed 2017-03-06 | 910.28K shares derived: sum of 3 quarters · filed 2017-03-06 | 989.23K shares derived: sum of 4 quarters · filed 2017-03-06 | |
| 2014-12-31 | 23.95K shares derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-06 | 30.75K shares derived: sum of 2 quarters · filed 2017-03-06 | 109.70K shares derived: sum of 3 quarters · filed 2017-03-06 | 944.83K shares 10-K · filed 2017-03-06 | |
| 2014-09-30 | 6.80K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-06 | 85.75K shares derived: sum of 2 quarters · filed 2014-11-06 | 920.88K shares 10-Q · filed 2014-11-06 | 948.53K shares derived: sum of 4 quarters · filed 2016-03-03 | |
| 2014-06-30 | 78.95K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-07 | 914.08K shares 10-Q · filed 2014-08-07 | 941.73K shares derived: sum of 3 quarters · filed 2016-03-03 | 949.58K shares derived: sum of 4 quarters · filed 2016-03-03 | |
| 2014-03-31 | 835.13K shares 10-Q · filed 2014-05-07 | 862.78K shares derived: sum of 2 quarters · filed 2016-03-03 | 870.63K shares derived: sum of 3 quarters · filed 2016-03-03 | -2.46M shares derived: sum of 4 quarters · filed 2016-03-03 | |
| 2013-12-31 | 27.65K shares derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-03 | 35.50K shares derived: sum of 2 quarters · filed 2016-03-03 | -3.30M shares derived: sum of 3 quarters · filed 2016-03-03 | 797.63K shares 10-K · filed 2016-03-03 | |
| 2013-09-30 | 7.85K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-06 | -3.33M shares derived: sum of 2 quarters · filed 2013-11-06 | 769.98K shares 10-Q · filed 2013-11-06 | -1.23M shares derived: sum of 4 quarters · filed 2015-03-06 | |
| 2013-06-30 | -3.33M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-07 | 762.13K shares 10-Q · filed 2013-08-07 | -1.23M shares derived: sum of 3 quarters · filed 2015-03-06 | -1.21M shares derived: sum of 4 quarters · filed 2015-03-06 | |
| 2013-03-31 | 4.10M shares 10-Q · filed 2013-05-08 | 2.10M shares derived: sum of 2 quarters · filed 2015-03-06 | 2.12M shares derived: sum of 3 quarters · filed 2015-03-06 | ||
| 2012-12-31 | -2.00M shares derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-06 | -1.98M shares derived: sum of 2 quarters · filed 2015-03-06 | 403.11K shares 10-K · filed 2015-03-06 | 2.42M shares 10-K · filed 2013-03-15 | |
| 2012-09-30 | 20.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-07 | 2.40M shares 10-Q · filed 2012-11-07 | |||
| 2012-06-30 | 2.38M shares 10-Q · filed 2012-08-06 | ||||
| 2011-12-31 | 425.42K shares 10-K · filed 2014-03-07 | 2.55M shares 10-K · filed 2013-03-15 | |||
| 2010-12-31 | 2.04M shares 10-K · filed 2013-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |